Royalty Pharma (RPRX) Projected to Post Quarterly Earnings on Wednesday

Royalty Pharma (NASDAQ:RPRX) is expected to be issuing its Q1 2026 results before the market opens on Wednesday, May 6th. Analysts expect the company to announce earnings of $1.22 per share and revenue of $881.6240 million for the quarter. Parties are encouraged to explore the company’s upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Wednesday, May 6, 2026 at 8:00 AM ET.

Royalty Pharma (NASDAQ:RPRX) last posted its earnings results on Wednesday, February 11th. The biopharmaceutical company reported $1.46 EPS for the quarter, topping the consensus estimate of $1.33 by $0.13. The company had revenue of $621.99 million during the quarter, compared to the consensus estimate of $839.97 million. Royalty Pharma had a net margin of 32.38% and a return on equity of 28.21%. On average, analysts expect Royalty Pharma to post $5 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Royalty Pharma Stock Up 0.9%

RPRX stock traded up $0.43 during trading hours on Tuesday, hitting $50.63. The company’s stock had a trading volume of 1,989,825 shares, compared to its average volume of 3,478,046. The company has a quick ratio of 2.40, a current ratio of 2.40 and a debt-to-equity ratio of 0.88. The company has a market capitalization of $29.21 billion, a PE ratio of 37.47, a price-to-earnings-growth ratio of 3.16 and a beta of 0.40. Royalty Pharma has a 12 month low of $31.97 and a 12 month high of $50.82. The stock has a 50 day moving average price of $47.31 and a two-hundred day moving average price of $42.45.

Royalty Pharma Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 10th. Investors of record on Friday, May 15th will be issued a dividend of $0.235 per share. This represents a $0.94 annualized dividend and a dividend yield of 1.9%. The ex-dividend date of this dividend is Friday, May 15th. Royalty Pharma’s dividend payout ratio is currently 69.63%.

Insider Buying and Selling

In related news, CFO Terrance P. Coyne sold 34,791 shares of the company’s stock in a transaction on Tuesday, April 28th. The shares were sold at an average price of $49.78, for a total transaction of $1,731,895.98. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 159,327 shares of company stock worth $7,497,758. 18.84% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Royalty Pharma

Several large investors have recently bought and sold shares of the stock. Larson Financial Group LLC raised its stake in Royalty Pharma by 31.9% during the 3rd quarter. Larson Financial Group LLC now owns 1,264 shares of the biopharmaceutical company’s stock valued at $45,000 after purchasing an additional 306 shares during the last quarter. Stifel Financial Corp raised its stake in Royalty Pharma by 2.0% during the 4th quarter. Stifel Financial Corp now owns 20,215 shares of the biopharmaceutical company’s stock valued at $781,000 after purchasing an additional 387 shares during the last quarter. CIBC Private Wealth Group LLC raised its stake in Royalty Pharma by 66.4% during the 4th quarter. CIBC Private Wealth Group LLC now owns 1,118 shares of the biopharmaceutical company’s stock valued at $43,000 after purchasing an additional 446 shares during the last quarter. Blair William & Co. IL raised its stake in Royalty Pharma by 6.8% during the 3rd quarter. Blair William & Co. IL now owns 7,263 shares of the biopharmaceutical company’s stock valued at $256,000 after purchasing an additional 462 shares during the last quarter. Finally, Transamerica Financial Advisors LLC raised its stake in Royalty Pharma by 10.7% during the 4th quarter. Transamerica Financial Advisors LLC now owns 5,158 shares of the biopharmaceutical company’s stock valued at $199,000 after purchasing an additional 498 shares during the last quarter. 54.35% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on RPRX. Wall Street Zen downgraded shares of Royalty Pharma from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 14th. UBS Group upped their price objective on shares of Royalty Pharma from $51.00 to $57.00 and gave the stock a “buy” rating in a report on Tuesday, April 21st. Morgan Stanley upped their price objective on shares of Royalty Pharma from $61.00 to $63.00 and gave the stock an “overweight” rating in a report on Friday, April 10th. Citigroup upped their price objective on shares of Royalty Pharma from $48.00 to $50.00 and gave the stock a “buy” rating in a report on Tuesday, January 27th. Finally, Weiss Ratings raised shares of Royalty Pharma from a “buy (b-)” rating to a “buy (b)” rating in a report on Friday. Six analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $50.33.

About Royalty Pharma

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.